Our 20th Patient-Focused Drug Development meeting: Enhancing the patient ’s voice in FDA’s approach to drug review and development

By: Theresa M. Mullin, Ph.D. Since the launch of the Patient Focused Drug Development program as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V), we have worked intensively to explore ways to enhance the … Continue reading →

Source: FDA Voice - October 4, 2016 Category: American Health Source Type: blogs